Fibromyalgia
Conditions
Keywords
fibromyalgia, lyrica, pregabalin
Brief summary
A 9-week randomized double-blind, multi-center study of 172 patients, who after 1 week baseline evaluation are randomized to either fixed dose pregabalin starting at 75 mg BID for one week and increased to 150 mg BID for 7 weeks or flexibly dosed pregabalin given BID (75-300 mg/d) increased gradually over 4 weeks then maintained at that same dosing for 4 weeks.It is proposed that use of flexible dosing combined with nightly dosing would have similar pain relief to fixed dosing, would improve adherence, would have less side effects and would be more likely to improve sleep.
Interventions
DRUGPregabalin
Fixed dosing of pregabalin: Week 1: 75 mg bid. Weeks 2 - 8: 150 mg bid. Week 9 (Days 57-60 and Days 61-63): 75 mg bid. Flexible dosing of pregabalin: Week 1: placebo in the AM and 75 mg nightly; Week 2: placebo in the AM and 150 mg nightly.; Week 3 placebo in the a.m., 225 mg nightly; Weeks 4 - 8 placebo in the a.m., 300 mg nightly. Week 9 (Days 57-60) placebo in the a.m,, 150 mg bid nightly and Days 61-63: placebo in the a.m., and 75 mg bid nightly.
Sponsors
Pfizer
Osteoporosis Medical Center, Beverly Hills, CA
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* diagnosis of fibromyalgia by ACR criteria * ambulatory patients * complete of 5 pain diaries during 1 week evaluation * other inclusion criteria may apply
Exclusion criteria
* pregnant or of childbearing potential not using contraceptives * use of pregabalin in the past * concomitant use of opioids or gabapentin * estimated creatinine clearance less than 60 * other criteria may apply
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pain score evaluation by NRS | 8 weeks | Least square mean change in Fibromyalgia pain at 8weeks compared to baseline utilizing an 11 point numerical rating scale daily pain diary (0 = no pain to 10 =worst possible pain) performed at daily awakening. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Patient Global Impression of Change | At weeks 4 and 8 | — |
| Discontinuation rate | 9 weeks | Discontinuation rates due to lack of efficacy and discontinuation rates due to adverse event. |
| Improvements in Wolfe Symptom Severity Score | 9 weeks | Wolfe Symptom Severity scales for pain, fatigue, trouble sleeping, trouble with anxiety or depression, trouble thinking or remembering, overall FM severity, problems awaking feeling unrefreshed |
Countries
United States
Outcome results
None listed